logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5993.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5993.produseast1
Neglected tropical diseases | Collections | MSF Science Portal
Neglected tropical diseases

Neglected tropical diseases

Each year hundreds of thousands of people die from a neglected tropical disease, while many more suffer serious illness or lifelong disability. Yet as we mark World Neglected Tropical Diseases (NTD) Day on 30th January, global progress towards eliminating these diseases is threatened by shifting global health priorities and declining investment in the wake of the Covid-19 pandemic.


The content collection linked below offers a snapshot of MSF’s work on managing some of the most deadly NTDs, finding better tools and models of care for highly affected populations, and advocating for greater access to care and increased global funding. Several authors describe our programs and lessons learned from a decade of treating snakebite victims in sub-Saharan Africa. Two studies evaluate shorter, less toxic treatment for visceral leischmaniasis, while a policy analysis proposes critical steps towards eliminating this horrific disease in East Africa. Last, reports from Sokoto, Nigeria describe the collaborative development of a comprehensive model of care for noma.

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (11)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (11)
  • CSV
  • BibTeX
  • EndNote

See more collections

Medical and humanitarian harms of restrictive European migration policies

Medical and humanitarian harms of restrictive European migrat...
Conflict, persecution, poverty, food insecurity and natural disasters—increasingly fueled by climate change—continue to drive migration globally. Yet many wealthy countries are doubling down on hostile policies to prevent people from seeking safety within their borders, thereby subjecting them to a wide range of harms. In a newly-published report MSF focuses on European Union and member state policies that intensify exposure to violence, exploitation, risk of drowning at sea, disease, and lack of access to basic health care and shelter, both within European Union borders and beyond. The Collection linked below presents this report alongside selected publications illustrating the broader context, based on quantitative studies and accounts from MSF patients and medical teams over nearly a decade of operational experience along the European migration route. From violent, squalid detention centers in Libya— where people intercepted by the EU-supported Libyan coast guard are forcibly returned —to perilous Mediterranean crossings in flimsy rubber boats and often abysmal reception centers and camps within the EU, it documents how these policies and practices further harm highly vulnerable people seeking safety and protection.
Noma

Noma
Healthcare needs of older people in humanitarian settings

Healthcare needs of older people in humanitarian settings
View All Collections

Noma, also known as cancrum oris, is a rapidly progressing life-threatening infection that affects the mouth and face. Noma is preventable and easy to treat if addressed in the early reversible stages, but most often deadly if untreated. The disease most commonly affects children who are chronically malnourished or whose immune systems are otherwise compromised. Noma affects an estimated 140,000 children annually. Noma was added to the WHO's list of Neglected Tropical Diseases in 2023.


MSF is working to discover more about noma. This collection highlights MSF's mixed methods research on treatment outcomes, burden of disease, attitudes towards the disease and other aspects of noma.


For more information on MSF's work on noma, you can also visit https://noma.msf.org/.

Globally, the number of older people is rapidly increasing, with those aged 60+ expected to more than double by 2050—yet in humanitarian crises, they remain one of the most neglected groups. Older adults often face higher risks due to chronic illnesses, mobility issues, and limited access to appropriate care, especially in low-resource or emergency settings. Despite these needs, humanitarian responses rarely prioritize them, and data on their health and mortality are often lacking.


This collection reflects MSF’s ongoing examination of its own data and practices to identify pathways toward more age-inclusive services in humanitarian crises. It includes analysis of data from MSF-supported mental health services, inpatient departments, and sexual violence services, and further offers several calls to action and reflections on why older people remain overlooked in humanitarian crises. However, MSF also acknowledges major challenges remain, including inadequate age-inclusive services, data gaps, and the need for more geriatric expertise.


Watch this space for more publications from a Lancet Healthy Longevity series on healthcare rights and needs of older people.


Journal Article
|
Research

Melioidosis in Mali: a retrospective observational study

Lichtenegger S, Klugherz I, Wagner GE, Michel J, Mollo B,  et al.
2025-11-01 • Lancet Global Health
2025-11-01 • Lancet Global Health

BACKGROUND

Melioidosis is a neglected tropical bacterial infection with a high mortality rate caused by the Gram-negative soil bacterium Burkholderia pseudomall...

Conference Material
|
Abstract

The microbiology of noma: insights from a pilot deep shotgun metagenomic project of patients presenting at the Noma Children’s Hospital, Sokoto, Nigeria

Olaleye M, O'Ferrell AM, Goodman R, Kabila DW, Peters M,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025
Journal Article
|
Commentary

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

Potet J, Singh SN, Ritmeijer KKD, Sisay K, Alcoba G,  et al.
2022-12-21 • Toxicon: X
2022-12-21 • Toxicon: X
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each y...
Journal Article
|
Research

AmBisome monotherapy and combination AmBisome - miltefosine therapy for the treatment of visceral leishmaniasis in patients co-infected with HIV in India: a randomised open label, parallel arm, phase 3 trial

Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...
Journal Article
|
Research

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...
Journal Article
|
Research

The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018

Naylor-Leyland G, Collin SM, Gatluak F, den Boer ML, Alves F,  et al.
2022-08-18 • PLOS Neglected Tropical Diseases
2022-08-18 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral Leishmaniasis (VL) is endemic in South Sudan, manifesting periodically in major outbreaks. Provision of treatment during endemic periods and as an emergency respo...
Journal Article
|
Review

Towards the elimination of visceral leishmaniasis as a public health problem in East Africa: reflections on an enhanced control strategy and a call for action

Alvar J, den Boer ML, Dagne DA
2021-12-01 • Lancet Global Health
2021-12-01 • Lancet Global Health
East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only sli...
Journal Article
|
Review

Access to antivenoms in the developing world: a multidisciplinary analysis

Potet J, Beran D, Ray N, Alcoba G, Habib AG,  et al.
2021-10-26 • Toxicon: X
2021-10-26 • Toxicon: X
Access to safe, effective, quality-assured antivenom products that are tailored to endemic venomous snake species is a crucial component of recent coordinated efforts to reduce the globa...
Journal Article
|
Commentary

Control of visceral leishmaniasis in East Africa: fragile progress, new threats

Dahl EH, Hamdan M, Mabrouk L, Matendechero S, Mengistie TB,  et al.
2021-08-13 • BMJ Global Health
2021-08-13 • BMJ Global Health
SUMMARY BOX

• Significant progress has been made in reducing the global burden of visceral leishmaniasis, but new threats are on the horizon.
• Funding for elimination of ...
Journal Article
|
Commentary

Model of care, Noma Children’s Hospital, northwest Nigeria

Isah S, Amirtharajah M, Farley ES, Adetunji AS, Samuel J,  et al.
2021-06-03 • Tropical Medicine and International Health
2021-06-03 • Tropical Medicine and International Health
The Nigerian Ministry of Health has been offering care for noma patients for many years at the Noma Children's Hospital (NCH) in Sokoto, northwest Nigeria, and Médecins Sans Frontières h...
Conference Material
|
Poster

Outcomes and effectiveness of antivenom treatments in snakebite patients in north-west Ethiopia: retrospective cohort

Steegemans IM, Sisay K, Nshimiyimana E, Gebrewold G, Piening T,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research